Impact Factor
3.68
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.21
1,821 total citations
h5-index
43
h5 depth signal
Cited share
69.0%
403 of 584
Total citations
1,821
Citation footprint
Metric signal
3.47
External metric anchor
Self-citation
7.7%
140 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,157
Germany
663
France
662
Italy
596
United Kingdom
501
Citing Fields of Research
Hematology
2,784
Lymphomas
617
Immunology
478
Transplantation
421
Stem Cell Biology
144
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
11,524
Articles tracked across the journal lifetime
Indexed publication set
584
403 cited publications
Last 12 months
340
28.3 publications/month
Open access share
32.4%
110 OA publications in the last year
Leading citing country
United States
1,157 citing publications
Leading citing field
Hematology
2,784 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1986-
v1n1, 1986-
Active Coverage
Research Focus & Classification
Indexed Subjects
Hematology
Broad Categories
Transplantation
Hematology
MeSH Descriptors
Bone Marrow Transplantation
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
DOI 10.1038/s41409-026-03068-9
Open DOI
The prognostic impact of CEBPA mutation in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation
The presence of mutations in basic leucine zipper (bZIP) region of the CEBPA gene in patients with acute myeloid leukemia (AML) is defined as a favorable risk marker according to the guidelines. A total of 173 CEBPA-mutated AML patients ...
03
04
DOI 10.1038/s41409-026-03067-w
Open DOI
Bridging therapy in pediatric and AYA patients under 25 years with relapsed/refractory B-ALL undergoing anti-CD19 CAR-T therapy: a multicenter retrospective study by the Spanish group GETH-TC
CAR-T therapy is a powerful treatment for pediatric B-cell acute lymphoblastic leukemia (B-ALL). However, the impact of bridging therapy prior to CAR-T infusion on patient outcomes remains insufficiently explored. In this retrospective s...
05
DOI 10.1038/s41409-026-03069-8
Open DOI
Pleuroparenchymal fibroelastosis after allogeneic hematopoietic stem cell transplantation: Risk factors and longitudinal pulmonary function trajectories in a multicenter cohort
Pleuroparenchymal fibroelastosis (PPFE) is an uncommon but serious late pulmonary complication after hematopoietic stem cell transplantation (HSCT), frequently resulting in the need for lung transplantation and contributing substantially...
06
07
DOI 10.1038/s41409-026-03059-w
Open DOI
Hyperacute Graft-Versus-Host Disease
08
09
DOI 10.1038/s41409-026-03056-z
Open DOI
Itacitinib plus calcineurin inhibitor–based therapy for prophylaxis of graft-versus-host disease: GRAVITAS-119 results
10
DOI 10.1038/s41409-026-03063-0
Open DOI
Peri-transplant ruxolitinib in myelofibrosis patients undergoing αβTCR and CD19-depleted stem cell transplantation
Bibliographical & Catalog Notes
Title from cover.
Some vols. have supplements.
One supplement each year consists of the Proceedings of the annual meeting of the European Cooperative Group for Bone Marrow Transplantation.
Also issued online.
Vol. 13, no. 1 (JAN 1994)19960129 Notice published Printed on acid-free paper that meets the full ANSI standard for Permanent Paper